In nonalcoholic steatohepatitis, PKCδ promotes hepatic oxidative stress and apoptosis [281], contributing to fibrosis, while inhibition of PKCδ via the TGFβ1 pathway significantly attenuates fibrotic progression [282]. Here, PRKCD is linked to metabolic dysfunction-associated steatohepatitis.